← The Wire
NKTRNasdaq
NEKTAR THERAPEUTICS
Pharmaceutical Preparations · DE · CIK 906709
Nektar Therapeutics develops and researches new drug candidates for various therapeutic areas
red 8-K · 90d
$2.01B
Market cap
$65.39
Last close
+2.7%
1D
-0.5%
5D
1.2M
Volume
Price · last 39 sessions-24.7%
May 4L $56.23 · H $86.89Jun 29
258
Total filings
Jun 5, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 5, 2026424B5424B5May 8, 20268-KExecutive Change · Material AgreementMay 8, 202610-Q10-QMay 8, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 20268-KMaterial Agreement · Company UpdateApr 23, 2026424B5424B5Apr 23, 2026424B5424B5Apr 20, 20268-KReg FD DisclosureApr 20, 20268-KReg FD Disclosure · Company UpdateApr 20, 202610-K10-KMar 13, 20268-KResults of OperationsMar 12, 20268-KMaterial Agreement · Company UpdateFeb 13, 2026424B5424B5Feb 13, 2026424B5424B5Feb 10, 20268-KReg FD DisclosureFeb 10, 20268-KReg FD Disclosure · Company UpdateFeb 10, 20268-KReg FD DisclosureJan 27, 20268-KReg FD Disclosure · Company UpdateDec 16, 20258-KExecutive ChangeNov 21, 2025424B5424B5Nov 12, 20258-KReg FD Disclosure · Company UpdateNov 10, 202510-Q10-QNov 7, 20258-KResults of OperationsNov 6, 20258-KReg FD Disclosure · Company UpdateSep 18, 202510-Q10-QAug 8, 20258-KResults of OperationsAug 7, 20258-KMaterial Agreement · Company UpdateJul 1, 2025424B5424B5Jul 1, 2025424B5424B5Jun 30, 20258-KCompany UpdateJun 27, 20258-KReg FD Disclosure · Company UpdateJun 24, 20258-KBylaw AmendmentJun 6, 20258-KCompany UpdateJun 4, 20258-KShareholder VoteMay 28, 202510-Q10-QMay 9, 20258-KResults of OperationsMay 8, 2025DEF 14ADEF 14AApr 25, 20258-KDelisting NoticeApr 4, 20258-KMaterial AgreementMar 28, 202510-K10-KMar 14, 20258-KResults of OperationsMar 12, 20258-KCompany UpdateFeb 24, 20258-KCompany UpdateFeb 4, 20258-KAcquisition / DispositionDec 2, 2024SC 13GSC 13GNov 14, 2024SC 13GSC 13GNov 8, 202410-Q10-QNov 8, 20248-KResults of OperationsNov 7, 20248-KMaterial Agreement · Reg FD DisclosureNov 4, 2024SC 13GSC 13GOct 22, 202410-Q10-QAug 9, 20248-KResults of OperationsAug 8, 20248-KShareholder VoteJun 6, 202410-Q10-QMay 10, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KCompany UpdateApr 17, 2024SC 13GSC 13GMar 15, 202410-K10-KMar 5, 20248-KMaterial Agreement · Results of OperationsMar 4, 20248-KMaterial Agreement · Equity IssuanceMar 4, 20248-KAgreement Terminated · Company UpdateFeb 16, 20248-KResults of Operations · Reg FD DisclosureJan 10, 20248-KDelisting NoticeNov 27, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 7, 20238-KAgreement TerminatedSep 8, 2023SC 13GSC 13GAug 17, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 8, 20238-KReg FD Disclosure · Company UpdateAug 7, 2023SC 13GSC 13GJul 3, 20238-KExecutive ChangeJun 23, 20238-KShareholder VoteJun 9, 20238-KDelisting NoticeJun 2, 202310-Q10-QMay 10, 2023
Insider Activity
In the 90 days to Feb 18, 2026: 3 sold $399K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Robin Howard WPresident & CEO | Sell | 423 | $73.00 | $31K |
| Feb 18, 2026 | Zalevsky JonathanChief R&D Officer | Sell | 180 | $73.00 | $13K |
| Jan 20, 2026 | Zalevsky JonathanChief R&D Officer | Sell | 3,867 | $35.67 | $138K |
| Nov 25, 2025 | Robin Howard WPresident & CEO | Sell | 2,207 | $54.28 | $120K |
| Nov 25, 2025 | Zalevsky JonathanChief R&D Officer | Sell | 1,157 | $54.28 | $63K |
| Nov 25, 2025 | Wilson Mark AndrewChief Legal Officer | Sell | 630 | $54.28 | $34K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance